<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02787863</url>
  </required_header>
  <id_info>
    <org_study_id>115030370013</org_study_id>
    <nct_id>NCT02787863</nct_id>
  </id_info>
  <brief_title>Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology</brief_title>
  <official_title>Pathogenetic Justification and Clinical and Immunological Efficiency of Application Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mikhael Petrovich Kostinov</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Russian Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Goal: to to examine the formation of postvaccination immunity and evaluate the therapeutic
      effect of bacterial vaccines in patients with inflammation diseases of bronchopulmonary
      system. Objectives of the study: assessment of microbiocenosis mucous membranes of the upper
      respiratory tract in patients with bronchopulmonary pathology before and after use of
      bacterial vaccines. Identification of mayor lymphocytes subpopulations in patients in the
      dynamics of the vaccination process. Study the profile of humoral immune response in patients
      under different schemes of vaccination. Assessment of the clinic and functional status
      bronchopulmonary system in the immunized patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods:

        1. Immunoglobulin G (IgG)-antibodies against Streptococcus pneumoniae (S. pneumoniae) -
           solid-phase enzyme-linked immunoelectrodiffusion essay (ELISA).

        2. General levels of Immunoglobulin A (IgA), Immunoglobulin M (IgM), IgG, Immunoglobulin E
           (IgE) in sera - radial immunodiffusion.

        3. Phagocytic activity (granulocytes, monocytes), nitroblue tetrazolium test;
           T-lymphocytes, T-helpers (cluster of differentiation, CD3+CD4+), cytotoxic T-lymphocytes
           (СD3+CD8+), B-lymphocytes (CD19+); NK-cells (CD3-CD16+CD56+), NKT-cells
           (CD3+CD16+CD56+), activated T-cells (human leucocyte antigens, CD3+HLA DR+), CD3-HLA
           DR+.

        4. Microbiological examination of sputum.

        5. Determining the clinical effectiveness of vaccination.

             -  the number of exacerbations of chronic bronchopulmonary pathology for the year
                prior to vaccination and during the first and fourth years after vaccination;

             -  the number of courses of antibiotic therapy a year prior to vaccination and during
                the first and fourth years after immunization;

             -  the number of hospitalizations for acute exacerbations of chronic bronchopulmonary
                disease during the year prior to vaccination and during the first and fourth years
                after immunization.

        6. Method of estimating quality of life associated with health in patients with chronic
           bronchopulmonary pathology (asthma control questionnaire (ACQ-5), COPD assessment test
           (CAT)).

      Characteristics of variables (arms 1-8).

        1. The age of patients (years): mean (standard deviation) [min; median; max] for normally
           distributed variables; median [Q25; Q75] - for variables with distribution different
           from normal.

        2. Gender: male/female.

        3. Indicators of immune status

             -  IgG antibodies to S. pneumoniae

             -  IgA, g/l [0,4-3,5]

             -  IgM, g/l [0,7-2,8]

             -  IgG, g/l [8-18]

             -  IgE, IU/ml [&lt; 100]

             -  Phagocytic index (granulocyte), % [82-90]

             -  Phagocytic index (monocytes), % [75-85]

             -  The participation rate of spontaneous NBT-test (neutrophils), % with intensity of
                0.2.e. [7-14]

             -  The index of activity induced NBT-test (neutrophils), % if intensity &gt;of 0.36.e.
                [&gt;28]

             -  The percentage of NBT-positive cells in spontaneous test, % [2-19]

             -  Circulating immune complexes (CEC) cond. units [0,055-0,11]

             -  CD3+, % [55-80]

             -  CD3+CD4+, % [31-49]

             -  CD3+CD8+, % [12-30]

             -  CD19+, % [5-19]

             -  CD3-CD16+CD56+, % [6-20]

             -  CD3+CD16+CD56+, % [&lt;10]

             -  CD3-HLA DR+, % [5-20]

             -  CD3+HLA DR+, % [&lt;12]

             -  CD45RO. The reference value = 0,2.

        4. Microbiological examination of sputum: frequency of selection of certain microorganisms
           are presented as absolute number of cases and % in the respective groups.

        5. Evaluation of early post-vaccination period

             -  The General condition (satisfactory/unsatisfactory)

             -  Local reactions: pain (n/%), redness (n/%, cm), consolidation (n/%, cm)

             -  General reactions:

                  -  Temperature 37,0-37,5 (n/%)

                  -  Temperature of 37.6-38,5 (n/%)

                  -  A temperature of 38.6 and &gt; (n/%)

                  -  Headache (n/%)

                  -  Malaise, fatigue (n/%)

                  -  Joint pain (n/%)

                  -  Muscle pain (n/%)

        6. Health related quality of life (HRQoL): CAT-test (for Chronic obstructive pulmonary
           disease (COPD) patients), ACQ-5 (for asthma patients).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 6, 2012</start_date>
  <completion_date type="Actual">December 31, 2016</completion_date>
  <primary_completion_date type="Actual">December 31, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Without Exacerbations of the Underlying Disease, Antibiotic Use and Hospitalisation.</measure>
    <time_frame>Baseline (1 year prior to vaccination), 1 year after vaccination, 4 years after vaccination</time_frame>
    <description>Number of patients without exacerbations of the underlying disease, antibiotic use and hospitalisation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Exacerbations of the Underlying Disease, Antibiotic Use and Hospitalisation</measure>
    <time_frame>Baseline (1 year prior to vaccination), 1 year after vaccination, 4 years after vaccination</time_frame>
    <description>The number of exacerbations of the underlying disease, antibiotic use and hospitalisation. The average number of exacerbations per 1 patient = total exacerbations in the group / number of patients in the group. This is not a mean value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seeding Frequency S. Pneumoniae From Sputum in Patients With COPD</measure>
    <time_frame>Baseline, after 1 and 4 years after vaccination</time_frame>
    <description>Seeding frequency S. pneumoniae from sputum in patients with COPD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average CAT (COPD) and ACQ-5 (Asthma) Score</measure>
    <time_frame>Baseline, after 1 and 4 years after vaccination</time_frame>
    <description>CAT — COPD Assessment Test, min. = 0, max. = 40, higher scores mean a worse outcome.
ACQ-5 — Asthma control questionnaire, min. = 0, max. = 6, higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phagocytic Activity in Patients With COPD at Baseline, 1, 2, and 6 Weeks After PCV13 and PPV13 Vaccination</measure>
    <time_frame>Baseline, 1, 2, 6 weeks after PCV13 and PPV13 vaccination</time_frame>
    <description>Phagocytic index (granulocytes), phagocytic index (monocytes), activity of a spontaneous HCT test (neutrophils), activity of an induced HCT test (neutrophils), percentage of HCT-positive white blood cells in a spontaneous test. The phagocytic index was calculated according to the following formula: phagocytic index = (total number of engulfed cells/total number of counted macrophages) × (number of macrophages containing engulfed cells/total number of counted macrophages) × 100 (phagocytic index)
The phagocytic index was calculated by counting at least 100 bacteria phagocytized by certain number of phagocytic cells/macrophages and expressed following formula (Mamnur Rashid 1997):
Phagocytic index = Total no. of phagocytized bacteria /No of phagocytic cells phagocytizing bacteria.
Activation index = % formazan positive cells (FPC) in NBT stimulated / % formazan positive cells (FPC) in NBT Spontaneous.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunophenotype of Blood Lymphocytes in Patients With COPD</measure>
    <time_frame>Baseline, 1, 2, 6 weeks after PCV13 and PPV13 vaccination</time_frame>
    <description>Immunophenotype of blood lymphocytes in patients with COPD at baseline, 1, 2 and 6 weeks after PCV13 and PPV23 vaccination. It was pre-specified to report data from only the &quot;COPD - Prevenar-13&quot; and the &quot;COPD - Pneumo-23&quot; Arms/Groups for this Outcome Measure&quot;. This is due to the fact that we tried to study the effect of PCV13 and PPV23 on immunity values. The study of the immunological effects of vaccination in the early post-vaccination period was carried out in 2 groups of patients: 20 patients with COPD vaccinated with PCV13; 20 patients with COPD vaccinated with PPV23. These patients were selected from patients of the main groups (COPD - Prevenar-13 (1), COPD - Pneumo-23 (3)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgA, IgM, IgG, IgE, Circulating Immune Complexes (CIC)</measure>
    <time_frame>Baseline, 1, 2, 6 weeks after PCV13 and PPV13 vaccination in COPD</time_frame>
    <description>IgA, IgM, IgG, IgE, circulating immune complexes (CIC) in serum at baseline, 1, 2 and 6 weeks after vaccination. It was pre-specified to report data from only the &quot;COPD - Prevenar-13&quot; and the &quot;COPD - Pneumo-23&quot; Arms/Groups for this Outcome Measure&quot;. This is due to the fact that we tried to study the effect of PCV13 and PPV23 on immunity values. The study of the immunological effects of vaccination in the early post-vaccination period was carried out in 2 groups of patients: 20 patients with COPD vaccinated with PCV13; 20 patients with COPD vaccinated with PPV23. These patients were selected from patients of the main groups (COPD - Prevenar-13 (1), COPD - Pneumo-23 (3)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD45RO</measure>
    <time_frame>Baseline, 1 and 4 years after vaccination</time_frame>
    <description>CD45RO expression on lymphocytes in serum at baseline, 1 and 4 years after vaccination. These patients were selected from patients of the main groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific IgG Levels in Vaccinated Patients With COPD to S. Pneumoniae Serotypes</measure>
    <time_frame>Baseline, 1 and 12 months after vaccination</time_frame>
    <description>Mean specific IgG levels in vaccinated patients with COPD to S. pneumoniae serotypes at baseline, 6 and 12 months after vaccination</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Asthma</condition>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>COPD with Prevenar-13 (1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>33 patients with COPD. Standard therapy with Prevenar-13.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asthma with Prevenar 13 (2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>34 patients with asthma. Standard therapy with Prevenar 13.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD with Pneumo-23 (3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 patients with COPD. Standard therapy with Pneumo-23.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asthma with Pneumo-23 (4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 patients with asthma. Standard therapy with Pneumo-23.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD with Pneumo-23/Prevenar-13 (5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>32 patients with COPD. Standard therapy, vaccinated with pneumococcal polysaccharide vaccine/pneumococcal conjugate vaccine (PPV23/PCV13).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asthma with Pneumo-23/Prevenar-13 (6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18 patients with Asthma. Standard therapy, vaccinated with PPV23/PCV13.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD with Prevenar-13/Pneumo-23 (7)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 patients with COPD. Standard therapy, vaccinated with PCV13/PPV23.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asthma with Prevenar-13/Pneumo-23 (8)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>27 patients with Asthma. Standard therapy, vaccinated with PCV13/PPV23.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevenar-13</intervention_name>
    <description>Conjugate 13 serotype pneumococcal vaccine</description>
    <arm_group_label>Asthma with Pneumo-23/Prevenar-13 (6)</arm_group_label>
    <arm_group_label>Asthma with Prevenar 13 (2)</arm_group_label>
    <arm_group_label>Asthma with Prevenar-13/Pneumo-23 (8)</arm_group_label>
    <arm_group_label>COPD with Pneumo-23/Prevenar-13 (5)</arm_group_label>
    <arm_group_label>COPD with Prevenar-13 (1)</arm_group_label>
    <arm_group_label>COPD with Prevenar-13/Pneumo-23 (7)</arm_group_label>
    <other_name>PCV13</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumo-23</intervention_name>
    <description>Polysaccharide 23-valent pneumococcal vaccine.</description>
    <arm_group_label>Asthma with Pneumo-23 (4)</arm_group_label>
    <arm_group_label>Asthma with Pneumo-23/Prevenar-13 (6)</arm_group_label>
    <arm_group_label>Asthma with Prevenar-13/Pneumo-23 (8)</arm_group_label>
    <arm_group_label>COPD with Pneumo-23 (3)</arm_group_label>
    <arm_group_label>COPD with Pneumo-23/Prevenar-13 (5)</arm_group_label>
    <arm_group_label>COPD with Prevenar-13/Pneumo-23 (7)</arm_group_label>
    <other_name>PPV23</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals of both sexes from 18 years with a diagnosis of COPD or Bronchial Asthma;

          -  The presence of signed and dated informed consent to participate in a clinical study;

          -  The ability to perform the requirements of the Protocol;

          -  For women of childbearing age is a negative result of a pregnancy test before
             vaccination.

        Diagnostic criteria for:

        - COPD: dyspnea: progressive (worsens over time), increases with exertion, persistent;
        chronic cough (may appear sporadically and may be unproductive); chronic expectoration; the
        impact of risk factors in the medical history (Smoking, occupational dust pollutants and
        chemicals); widespread wheeze on auscultation of the chest and/or distant wheezing in the
        chest; family history of COPD; spirometric data confirming the presence of fixed bronchial
        obstruction.

        Exclusion Criteria:

          -  Vaccination against pneumococcal infection in anamnesis;

          -  Application of preparations of immune globulin or blood transfusion within last three
             months prior to clinical studies;

          -  Prolonged use (more than 14 days) immunosuppressants or other immunosuppressive drugs
             within 6 months prior to the start of the study;

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including
             Human Immunodeficiency Virus (HIV) infection;

          -  A history or currently hematologic and other cancers;

          -  A positive reaction for HIV infection, viral hepatitis B and hepatitis C;

          -  The presence of respiratory, cardio-vascular insufficiency, impaired liver and kidney
             function, established during a physical examination at visit number 1;

          -  Pronounced congenital defects or serious chronic diseases in the acute stage,
             including any clinically important exacerbation of chronic diseases of the liver,
             kidney, cardiovascular, nervous system, mental diseases or metabolic disorders,
             confirmed by the history or objective examination (pulmonary: cystic fibrosis, lung
             abscess, empyema, active tuberculosis; extra-pulmonary: congestive heart failure,
             malabsorption, chronic renal and hepatic failure, cirrhosis, malignancy,
             immunodeficiency, cirrhosis of the liver);

          -  Severe allergic reactions in anamnesis, autoimmune disease;

          -  The presence of acute infectious and/or communicable illnesses within 1 month prior to
             study;

          -  History of chronic alcohol abuse and/or drug use;

          -  Exacerbation of chronic diseases;

          -  Breastfeeding;

          -  Pregnancy;

          -  Participation in any other clinical study within the last 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrei D Protasov, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samara State Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mikhael P Kostinov, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Sera and Vaccines RAS, Moscow</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mikhael P Kostinov, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of Sera and Vaccines RAS, Moscow</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aleksander V Zhestkov, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Samara State Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samara State Medical Univercity</name>
      <address>
        <city>Samara</city>
        <state>Samara Region</state>
        <zip>443099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Sera and Vaccines RAS</name>
      <address>
        <city>Moscow</city>
        <zip>105064</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <reference>
    <citation>Protasov AD. Pneumococcal vaccination in patients with chronic broncho-pulmonary disease (literature review). The Bulletin of Contemporary Clinical Medicine. 6(2): 60-65, 2013.</citation>
  </reference>
  <results_reference>
    <citation>Protasov AD, Zhestkov AV, Kostinov MP. First results of 13-valent pneumococcal conjugate vaccine treatment in patients with chronic bronchopulmonary diseases: evaluation safety and tolerability. Russian Allergology Journal 4: 18-23, 2013.</citation>
  </results_reference>
  <results_reference>
    <citation>Protasov AD.COMPARATIVE EVALUATION OF THE EFFECTIVENESS OF PNEUMOCOCCAL VACCINATION WITH 13-VALENT CONJUGATE AND 23-VALENT POLYSACCHARIDE VACCINE IN PATIENTS WITH COPD. Russian Allergology Journal 4: 12-17, 2014.</citation>
  </results_reference>
  <results_reference>
    <citation>Kostinov MP, Protasov AD, Zhestkov AV, Polishuk VB. Promising data with pneumococcal 13-valent conjugate vaccine in adult patients with chronic bronchopulmonary pathology. Pulmonology 4: 57-63, 2014</citation>
  </results_reference>
  <results_reference>
    <citation>Protasov AD. Comparative evaluation of the effectiveness of vaccination against pneumococcal infection in patients with bronchial asthma with the use of 13-valent conjugate and 23-valent polysaccharide vaccine. Pulmonology. 5: 52-56, 2014</citation>
  </results_reference>
  <results_reference>
    <citation>Kostinov MP, Zhestkov AV, Protasov AD, Kostinova TA, Pakhomov DV, Chebykina AV, Magarshak OO.Comparative analysis of dynamics of indicators of quality of life in patients with chronic obstructive pulmonary disease on the background of vaccination against pneumococcal disease using the 13-valent conjugate and 23-valent polysaccharide vaccine. Pulmonology 25(2): 163-166, 2015</citation>
  </results_reference>
  <results_reference>
    <citation>Protasov AD, Kostinov MP, Zhestkov AV, Shteiner ML, Magarshak OO, Kostinova TA, Ryzhov AA, Pakhomov DV, Blagovidov DA, Panina MI. [Choice of optimal vaccination tactics against pneumococcal infection from immunological and clinical standpoints in patients with chronic obstructive pulmonary disease]. Ter Arkh. 2016;88(5):62-69. doi: 10.17116/terarkh201688562-69. Russian.</citation>
    <PMID>27239929</PMID>
  </results_reference>
  <results_reference>
    <citation>Protasov AD, Zhestkov AV, Kostinov MP, Shteiner ML, Tezikov YV, Lipatov IS, Yastrebova NE, Kostinova AM, Ryzhov AA, Polishchuk VB. [Analysis of the effectiveness and long-term results of formation of adaptive immunity in the use of various medications and vaccination schemes against pneumococcal infection in patients with chronic obstructive pulmonary disease]. Ter Arkh. 2017;89(12. Vyp. 2):165-174. doi: 10.17116/terarkh20178912165-174. Russian.</citation>
    <PMID>29488477</PMID>
  </results_reference>
  <results_reference>
    <citation>Protasov AD, Zhestkov AV, Kostinov MP, Korymasov EA, Shteyner ML, Tezikov YV, Lipatov IS, Reshetnikova VP, Lavrent'yeva NE. Long-term clinical efficacy and a possible mechanism of action of different modes of pneumococcal vaccination in asthma patients. Pulmonology 28(2): 193-199, 2018.</citation>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 20, 2016</study_first_submitted>
  <study_first_submitted_qc>May 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2016</study_first_posted>
  <results_first_submitted>December 31, 2019</results_first_submitted>
  <results_first_submitted_qc>February 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 25, 2020</results_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Russian Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Mikhael Petrovich Kostinov</investigator_full_name>
    <investigator_title>MD, PhD, Chief of Laboratory of Vaccines and Allergotherapy of allergic diseases</investigator_title>
  </responsible_party>
  <keyword>Pneumococcal vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>IRB approval - 05 SEP 2012 (protocol #122, Samara State Medical University). Dates of recruitment period - 06 SEP 2012 - 07 JUL 2013. FPFV - 06 SEP 2012. LPLV - 07 JUL 2017. Types of location - Samara State Medical University, Institute of Sera and Vaccines RAS (Russian Federation).</recruitment_details>
      <pre_assignment_details>219 patients were examined and monitored for 4 years. Distributed in a row, first to the PCV13 group, then to the PPV23, PPV23/PCV13 and PCV13/PPV23 groups for COPD and asthma.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>COPD - Prevenar-13 (1)</title>
          <description>33 patients with COPD. Prevenar-13 (PCV13) vaccination.</description>
        </group>
        <group group_id="P2">
          <title>Asthma - Prevenar-13 (2)</title>
          <description>34 patients with asthma. Prevenar-13 (PCV13) vaccination.</description>
        </group>
        <group group_id="P3">
          <title>COPD - Pneumo-23 (3)</title>
          <description>25 patients with COPD. Pneumo-23 (PPV23) vaccination.</description>
        </group>
        <group group_id="P4">
          <title>Asthma - Pneumo-23 (4)</title>
          <description>25 patients with asthma. Pneumo-23 (PPV23) vaccination.</description>
        </group>
        <group group_id="P5">
          <title>COPD - Pneumo-23/Prevenar-13 (5)</title>
          <description>32 patients with COPD, PPV23/PCV13.
PPV23 vaccination was first, PCV13 vaccination was after 12 months after PPV23.</description>
        </group>
        <group group_id="P6">
          <title>Asthma - Pneumo-23/Prevenar-13 (6)</title>
          <description>18 patients with Asthma. PPV23/PCV13.
PPV23 vaccination was first, PCV13 vaccination was after 12 months after PPV23.</description>
        </group>
        <group group_id="P7">
          <title>COPD - Prevenar-13/Pneumo-23 (7)</title>
          <description>25 patients with COPD. PCV13/PPV23 vaccination.
PCV13 vaccination was first, PPV23 vaccination was after 2 months after PCV13.</description>
        </group>
        <group group_id="P8">
          <title>Asthma - Prevenar-13/Pneumo-23 (8)</title>
          <description>27 patients with Asthma. PCV13/PPV23 vaccination.
PCV13 vaccination was first, PPV23 vaccination was after 2 months after PCV13.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="32"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="25"/>
                <participants group_id="P8" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>1 Year After Vaccination</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="32"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="25"/>
                <participants group_id="P8" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>4 Years After Vaccination</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="32"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="25"/>
                <participants group_id="P8" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="32"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="25"/>
                <participants group_id="P8" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>COPD With Prevenar-13 (1)</title>
          <description>33 patients with COPD. Standard therapy with Prevenar-13.
Prevenar-13: Conjugate 13 serotype pneumococcal vaccine</description>
        </group>
        <group group_id="B2">
          <title>Asthma With Prevenar 13 (2)</title>
          <description>34 patients with asthma. Standard therapy with Prevenar 13.
Prevenar-13: Conjugate 13 serotype pneumococcal vaccine</description>
        </group>
        <group group_id="B3">
          <title>COPD With Pneumo-23 (3)</title>
          <description>25 patients with COPD. Standard therapy with Pneumo-23.
Pneumo-23: Polysaccharide 23-valent pneumococcal vaccine.</description>
        </group>
        <group group_id="B4">
          <title>Asthma With Pneumo-23 (4)</title>
          <description>25 patients with asthma. Standard therapy with Pneumo-23.
Pneumo-23: Polysaccharide 23-valent pneumococcal vaccine.</description>
        </group>
        <group group_id="B5">
          <title>COPD With Pneumo-23/Prevenar-13 (5)</title>
          <description>32 patients with COPD. Standard therapy, vaccinated with PPV23/PCV13.
Prevenar-13: Conjugate 13 serotype pneumococcal vaccine
Pneumo-23: Polysaccharide 23-valent pneumococcal vaccine.</description>
        </group>
        <group group_id="B6">
          <title>Asthma With Pneumo-23/Prevenar-13 (6)</title>
          <description>18 patients with Asthma. Standard therapy, vaccinated with PPV23/PCV13.
Prevenar-13: Conjugate 13 serotype pneumococcal vaccine
Pneumo-23: Polysaccharide 23-valent pneumococcal vaccine.</description>
        </group>
        <group group_id="B7">
          <title>COPD With Prevenar-13/Pneumo-23 (7)</title>
          <description>25 patients with COPD. Standard therapy, vaccinated with PCV13/PPV23.
Prevenar-13: Conjugate 13 serotype pneumococcal vaccine
Pneumo-23: Polysaccharide 23-valent pneumococcal vaccine.</description>
        </group>
        <group group_id="B8">
          <title>Asthma With Prevenar-13/Pneumo-23 (8)</title>
          <description>27 patients with Asthma. Standard therapy, vaccinated with PCV13/PPV23.
Prevenar-13: Conjugate 13 serotype pneumococcal vaccine
Pneumo-23: Polysaccharide 23-valent pneumococcal vaccine.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="25"/>
            <count group_id="B5" value="32"/>
            <count group_id="B6" value="18"/>
            <count group_id="B7" value="25"/>
            <count group_id="B8" value="27"/>
            <count group_id="B9" value="219"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>2 patients died of chronic pulmonary hypertension, 2 patients withdrawal of informed consent during 1-st year of the trial (1 subject of I group, I subject of II group, 2 subjects of III group).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="25"/>
                    <count group_id="B5" value="32"/>
                    <count group_id="B6" value="18"/>
                    <count group_id="B7" value="25"/>
                    <count group_id="B8" value="27"/>
                    <count group_id="B9" value="215"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="22"/>
                    <measurement group_id="B9" value="148"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <population>Measure Analysis Population Description: 2 patients died of chronic pulmonary hypertension, 2 patients withdrawal of informed consent during 1-st year of the trial (1 subject of I group, I subject of II group, 2 subjects of III group).</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="25"/>
                    <count group_id="B5" value="32"/>
                    <count group_id="B6" value="18"/>
                    <count group_id="B7" value="25"/>
                    <count group_id="B8" value="27"/>
                    <count group_id="B9" value="215"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.6" spread="8.7"/>
                    <measurement group_id="B2" value="52.5" spread="15.3"/>
                    <measurement group_id="B3" value="59" spread="12.4"/>
                    <measurement group_id="B4" value="49.1" spread="13.3"/>
                    <measurement group_id="B5" value="63.9" spread="10.9"/>
                    <measurement group_id="B6" value="48.5" spread="14.3"/>
                    <measurement group_id="B7" value="60.5" spread="12.1"/>
                    <measurement group_id="B8" value="49.3" spread="15.4"/>
                    <measurement group_id="B9" value="56.4" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Measure Analysis Population Description: 2 patients died of chronic pulmonary hypertension, 2 patients withdrawal of informed consent during 1-st year of the trial (1 subject of I group, I subject of II group, 2 subjects of III group).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="25"/>
                    <count group_id="B5" value="32"/>
                    <count group_id="B6" value="18"/>
                    <count group_id="B7" value="25"/>
                    <count group_id="B8" value="27"/>
                    <count group_id="B9" value="215"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="18"/>
                    <measurement group_id="B9" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="18"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="25"/>
                    <count group_id="B4" value="25"/>
                    <count group_id="B5" value="32"/>
                    <count group_id="B6" value="18"/>
                    <count group_id="B7" value="25"/>
                    <count group_id="B8" value="27"/>
                    <count group_id="B9" value="219"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="32"/>
                    <measurement group_id="B6" value="18"/>
                    <measurement group_id="B7" value="25"/>
                    <measurement group_id="B8" value="27"/>
                    <measurement group_id="B9" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Without Exacerbations of the Underlying Disease, Antibiotic Use and Hospitalisation.</title>
        <description>Number of patients without exacerbations of the underlying disease, antibiotic use and hospitalisation.</description>
        <time_frame>Baseline (1 year prior to vaccination), 1 year after vaccination, 4 years after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>COPD - Prevenar-13 (1)</title>
            <description>32 patients with COPD. Prevenar-13 (PCV13) vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Asthma - Prevenar-13 (2)</title>
            <description>33 patients with asthma. Prevenar-13 (PCV13) vaccination.</description>
          </group>
          <group group_id="O3">
            <title>COPD - Pneumo-23 (3)</title>
            <description>23 patients with COPD. Pneumo-23 (PPV23) vaccination.</description>
          </group>
          <group group_id="O4">
            <title>Asthma - Pneumo-23 (4)</title>
            <description>25 patients with asthma. Pneumo-23 (PPV23) vaccination.</description>
          </group>
          <group group_id="O5">
            <title>COPD - Pneumo-23/Prevenar-13 (5)</title>
            <description>32 patients with COPD, PPV23/PCV13.
PPV23 vaccination was first, PCV13 vaccination was after 12 months after PPV23.</description>
          </group>
          <group group_id="O6">
            <title>Asthma - Pneumo-23/Prevenar-13 (6)</title>
            <description>18 patients with Asthma. PPV23/PCV13.
PPV23 vaccination was first, PCV13 vaccination was after 12 months after PPV23.</description>
          </group>
          <group group_id="O7">
            <title>COPD - Prevenar-13/Pneumo-23 (7)</title>
            <description>25 patients with COPD. PCV13/PPV23 vaccination.
PCV13 vaccination was first, PPV23 vaccination was after 2 months after PCV13.</description>
          </group>
          <group group_id="O8">
            <title>Asthma - Prevenar-13/Pneumo-23 (8)</title>
            <description>27 patients with Asthma. PCV13/PPV23 vaccination.
PCV13 vaccination was first, PPV23 vaccination was after 2 months after PCV13.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Without Exacerbations of the Underlying Disease, Antibiotic Use and Hospitalisation.</title>
          <description>Number of patients without exacerbations of the underlying disease, antibiotic use and hospitalisation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="18"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Without exacerbations, 1 year prior to vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without exacerbations, 1 year after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="18"/>
                    <measurement group_id="O8" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without exacerbations, 4 years after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without antibiotics, 1 year prior to vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without antibiotics, 1 year after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="19"/>
                    <measurement group_id="O8" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without antibiotics, 4 years after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without hospitalisat, 1 year prior to vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without hospitalisat, 1 year after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="17"/>
                    <measurement group_id="O7" value="21"/>
                    <measurement group_id="O8" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without hospitalisat, 4 years after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="14"/>
                    <measurement group_id="O7" value="23"/>
                    <measurement group_id="O8" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Exacerbations of the Underlying Disease, Antibiotic Use and Hospitalisation</title>
        <description>The number of exacerbations of the underlying disease, antibiotic use and hospitalisation. The average number of exacerbations per 1 patient = total exacerbations in the group / number of patients in the group. This is not a mean value.</description>
        <time_frame>Baseline (1 year prior to vaccination), 1 year after vaccination, 4 years after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>COPD - Prevenar-13 (9)</title>
            <description>32 patients with COPD. Prevenar-13 (PCV13) vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Asthma - Prevenar-13 (10)</title>
            <description>33 patients with asthma. Prevenar-13 (PCV13) vaccination.</description>
          </group>
          <group group_id="O3">
            <title>COPD - Pneumo-23 (11)</title>
            <description>23 patients with COPD. Pneumo-23 (PPV23) vaccination.</description>
          </group>
          <group group_id="O4">
            <title>Asthma - Pneumo-23 (12)</title>
            <description>25 patients with asthma. Pneumo-23 (PPV23) vaccination.</description>
          </group>
          <group group_id="O5">
            <title>COPD - Pneumo-23/Prevenar-13 (13)</title>
            <description>32 patients with COPD, PPV23/PCV13.
PPV23 vaccination was first, PCV13 vaccination was after 12 months after PPV23.</description>
          </group>
          <group group_id="O6">
            <title>Asthma - Pneumo-23/Prevenar-13 (14)</title>
            <description>18 patients with Asthma. PPV23/PCV13.
PPV23 vaccination was first, PCV13 vaccination was after 12 months after PPV23.</description>
          </group>
          <group group_id="O7">
            <title>COPD - Prevenar-13/Pneumo-23 (15)</title>
            <description>25 patients with COPD. PCV13/PPV23 vaccination.
PCV13 vaccination was first, PPV23 vaccination was after 2 months after PCV13.</description>
          </group>
          <group group_id="O8">
            <title>Asthma - Prevenar-13/Pneumo-23 (16)</title>
            <description>27 patients with Asthma. PCV13/PPV23 vaccination.
PCV13 vaccination was first, PPV23 vaccination was after 2 months after PCV13.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Exacerbations of the Underlying Disease, Antibiotic Use and Hospitalisation</title>
          <description>The number of exacerbations of the underlying disease, antibiotic use and hospitalisation. The average number of exacerbations per 1 patient = total exacerbations in the group / number of patients in the group. This is not a mean value.</description>
          <units>Events per 1 patient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="18"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>The number of exacerbations (before vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97"/>
                    <measurement group_id="O2" value="2.24"/>
                    <measurement group_id="O3" value="2.13"/>
                    <measurement group_id="O4" value="2.68"/>
                    <measurement group_id="O5" value="2.22"/>
                    <measurement group_id="O6" value="2.39"/>
                    <measurement group_id="O7" value="2.52"/>
                    <measurement group_id="O8" value="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>The number of exacerbations (1-st year)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41"/>
                    <measurement group_id="O2" value="0.24"/>
                    <measurement group_id="O3" value="0.35"/>
                    <measurement group_id="O4" value="0.64"/>
                    <measurement group_id="O5" value="2.19"/>
                    <measurement group_id="O6" value="1.22"/>
                    <measurement group_id="O7" value="0.32"/>
                    <measurement group_id="O8" value="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>The number of exacerbations (4-th year)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16"/>
                    <measurement group_id="O2" value="0.85"/>
                    <measurement group_id="O3" value="1.52"/>
                    <measurement group_id="O4" value="1.2"/>
                    <measurement group_id="O5" value="1.72"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0.84"/>
                    <measurement group_id="O8" value="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>The number of antibiotic use (before vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66"/>
                    <measurement group_id="O2" value="1.12"/>
                    <measurement group_id="O3" value="1.87"/>
                    <measurement group_id="O4" value="1.68"/>
                    <measurement group_id="O5" value="1.91"/>
                    <measurement group_id="O6" value="1.72"/>
                    <measurement group_id="O7" value="2.12"/>
                    <measurement group_id="O8" value="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>The number of antibiotic use (1-st year))</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31"/>
                    <measurement group_id="O2" value="0.12"/>
                    <measurement group_id="O3" value="0.3"/>
                    <measurement group_id="O4" value="0.56"/>
                    <measurement group_id="O5" value="1.59"/>
                    <measurement group_id="O6" value="1.06"/>
                    <measurement group_id="O7" value="0.24"/>
                    <measurement group_id="O8" value="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>The number of antibiotic use (4-th year))</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19"/>
                    <measurement group_id="O2" value="0.69"/>
                    <measurement group_id="O3" value="1.69"/>
                    <measurement group_id="O4" value="1.44"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1.06"/>
                    <measurement group_id="O7" value="0.8"/>
                    <measurement group_id="O8" value="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>The number of hospitalisation (before vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88"/>
                    <measurement group_id="O2" value="0.73"/>
                    <measurement group_id="O3" value="0.87"/>
                    <measurement group_id="O4" value="0.56"/>
                    <measurement group_id="O5" value="0.94"/>
                    <measurement group_id="O6" value="0.56"/>
                    <measurement group_id="O7" value="0.84"/>
                    <measurement group_id="O8" value="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>The number of hospitalisation (1-st year)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13"/>
                    <measurement group_id="O2" value="0.03"/>
                    <measurement group_id="O3" value="0.09"/>
                    <measurement group_id="O4" value="0.04"/>
                    <measurement group_id="O5" value="0.47"/>
                    <measurement group_id="O6" value="0.06"/>
                    <measurement group_id="O7" value="0.16"/>
                    <measurement group_id="O8" value="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>The number of hospitalisation (4-th year)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63"/>
                    <measurement group_id="O2" value="0.3"/>
                    <measurement group_id="O3" value="0.96"/>
                    <measurement group_id="O4" value="0.56"/>
                    <measurement group_id="O5" value="0.47"/>
                    <measurement group_id="O6" value="0.44"/>
                    <measurement group_id="O7" value="0.2"/>
                    <measurement group_id="O8" value="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seeding Frequency S. Pneumoniae From Sputum in Patients With COPD</title>
        <description>Seeding frequency S. pneumoniae from sputum in patients with COPD</description>
        <time_frame>Baseline, after 1 and 4 years after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>COPD - Prevenar-13 (9)</title>
            <description>32 patients with COPD. Prevenar-13 (PCV13) vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Asthma - Prevenar-13 (10)</title>
            <description>33 patients with asthma. Prevenar-13 (PCV13) vaccination.</description>
          </group>
          <group group_id="O3">
            <title>COPD - Pneumo-23 (11)</title>
            <description>23 patients with COPD. Pneumo-23 (PPV23) vaccination.</description>
          </group>
          <group group_id="O4">
            <title>Asthma - Pneumo-23 (12)</title>
            <description>25 patients with asthma. Pneumo-23 (PPV23) vaccination.</description>
          </group>
          <group group_id="O5">
            <title>COPD - Pneumo-23/Prevenar-13 (13)</title>
            <description>32 patients with COPD, PPV23/PCV13.
PPV23 vaccination was first, PCV13 vaccination was after 12 months after PPV23.</description>
          </group>
          <group group_id="O6">
            <title>Asthma - Pneumo-23/Prevenar-13 (14)</title>
            <description>18 patients with Asthma. PPV23/PCV13.
PPV23 vaccination was first, PCV13 vaccination was after 12 months after PPV23.</description>
          </group>
          <group group_id="O7">
            <title>COPD - Prevenar-13/Pneumo-23 (15)</title>
            <description>25 patients with COPD. PCV13/PPV23 vaccination.
PCV13 vaccination was first, PPV23 vaccination was after 2 months after PCV13.</description>
          </group>
          <group group_id="O8">
            <title>Asthma - Prevenar-13/Pneumo-23 (16)</title>
            <description>27 patients with Asthma. PCV13/PPV23 vaccination.
PCV13 vaccination was first, PPV23 vaccination was after 2 months after PCV13.</description>
          </group>
        </group_list>
        <measure>
          <title>Seeding Frequency S. Pneumoniae From Sputum in Patients With COPD</title>
          <description>Seeding frequency S. pneumoniae from sputum in patients with COPD</description>
          <units>Number of Participants with S. Pneumonia</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="18"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>S. pneumoniae in sputum at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="14"/>
                    <measurement group_id="O8" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S. pneumoniae in sputum after 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S. pneumoniae in sputum after 4 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average CAT (COPD) and ACQ-5 (Asthma) Score</title>
        <description>CAT — COPD Assessment Test, min. = 0, max. = 40, higher scores mean a worse outcome.
ACQ-5 — Asthma control questionnaire, min. = 0, max. = 6, higher scores mean a worse outcome.</description>
        <time_frame>Baseline, after 1 and 4 years after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>COPD - Prevenar-13 (9)</title>
            <description>32 patients with COPD. Prevenar-13 (PCV13) vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Asthma - Prevenar-13 (10)</title>
            <description>33 patients with asthma. Prevenar-13 (PCV13) vaccination.</description>
          </group>
          <group group_id="O3">
            <title>COPD - Pneumo-23 (11)</title>
            <description>23 patients with COPD. Pneumo-23 (PPV23) vaccination.</description>
          </group>
          <group group_id="O4">
            <title>Asthma - Pneumo-23 (12)</title>
            <description>25 patients with asthma. Pneumo-23 (PPV23) vaccination.</description>
          </group>
          <group group_id="O5">
            <title>COPD - Pneumo-23/Prevenar-13 (13)</title>
            <description>32 patients with COPD, PPV23/PCV13.
PPV23 vaccination was first, PCV13 vaccination was after 12 months after PPV23.</description>
          </group>
          <group group_id="O6">
            <title>Asthma - Pneumo-23/Prevenar-13 (14)</title>
            <description>18 patients with Asthma. PPV23/PCV13.
PPV23 vaccination was first, PCV13 vaccination was after 12 months after PPV23.</description>
          </group>
          <group group_id="O7">
            <title>COPD - Prevenar-13/Pneumo-23 (15)</title>
            <description>25 patients with COPD. PCV13/PPV23 vaccination.
PCV13 vaccination was first, PPV23 vaccination was after 2 months after PCV13.</description>
          </group>
          <group group_id="O8">
            <title>Asthma - Prevenar-13/Pneumo-23 (16)</title>
            <description>27 patients with Asthma. PCV13/PPV23 vaccination.
PCV13 vaccination was first, PPV23 vaccination was after 2 months after PCV13.</description>
          </group>
        </group_list>
        <measure>
          <title>Average CAT (COPD) and ACQ-5 (Asthma) Score</title>
          <description>CAT — COPD Assessment Test, min. = 0, max. = 40, higher scores mean a worse outcome.
ACQ-5 — Asthma control questionnaire, min. = 0, max. = 6, higher scores mean a worse outcome.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="18"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8" lower_limit="3" upper_limit="38"/>
                    <measurement group_id="O2" value="1.8" lower_limit="0.6" upper_limit="2.2"/>
                    <measurement group_id="O3" value="22.8" lower_limit="2" upper_limit="37"/>
                    <measurement group_id="O4" value="2" lower_limit="1.4" upper_limit="2.2"/>
                    <measurement group_id="O5" value="16.8" lower_limit="4" upper_limit="34"/>
                    <measurement group_id="O6" value="1.1" lower_limit="0.5" upper_limit="2.2"/>
                    <measurement group_id="O7" value="23.4" lower_limit="3" upper_limit="39"/>
                    <measurement group_id="O8" value="1.6" lower_limit="0" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="7" upper_limit="19.5"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.2" upper_limit="1"/>
                    <measurement group_id="O3" value="14" lower_limit="6.5" upper_limit="20"/>
                    <measurement group_id="O4" value="0.8" lower_limit="0.4" upper_limit="2"/>
                    <measurement group_id="O5" value="11.5" lower_limit="6" upper_limit="15.8"/>
                    <measurement group_id="O6" value="0.5" lower_limit="0.2" upper_limit="1.1"/>
                    <measurement group_id="O7" value="11" lower_limit="8" upper_limit="20"/>
                    <measurement group_id="O8" value="0.4" lower_limit="0.2" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 years after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" lower_limit="5" upper_limit="32"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.4" upper_limit="1.4"/>
                    <measurement group_id="O3" value="20.5" lower_limit="4" upper_limit="35"/>
                    <measurement group_id="O4" value="1.4" lower_limit="1" upper_limit="1.8"/>
                    <measurement group_id="O5" value="15.1" lower_limit="4" upper_limit="28"/>
                    <measurement group_id="O6" value="0.8" lower_limit="0.4" upper_limit="1.35"/>
                    <measurement group_id="O7" value="19" lower_limit="12" upper_limit="24"/>
                    <measurement group_id="O8" value="1" lower_limit="0.5" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phagocytic Activity in Patients With COPD at Baseline, 1, 2, and 6 Weeks After PCV13 and PPV13 Vaccination</title>
        <description>Phagocytic index (granulocytes), phagocytic index (monocytes), activity of a spontaneous HCT test (neutrophils), activity of an induced HCT test (neutrophils), percentage of HCT-positive white blood cells in a spontaneous test. The phagocytic index was calculated according to the following formula: phagocytic index = (total number of engulfed cells/total number of counted macrophages) × (number of macrophages containing engulfed cells/total number of counted macrophages) × 100 (phagocytic index)
The phagocytic index was calculated by counting at least 100 bacteria phagocytized by certain number of phagocytic cells/macrophages and expressed following formula (Mamnur Rashid 1997):
Phagocytic index = Total no. of phagocytized bacteria /No of phagocytic cells phagocytizing bacteria.
Activation index = % formazan positive cells (FPC) in NBT stimulated / % formazan positive cells (FPC) in NBT Spontaneous.</description>
        <time_frame>Baseline, 1, 2, 6 weeks after PCV13 and PPV13 vaccination</time_frame>
        <population>Phagocytic index (granulocytes) — %, phagocytic index (monocytes) — %, activity of a spontaneous HCT test (neutrophils) — %, activity of an induced HCT test (neutrophils) — %, percentage of HCT-positive white blood cells in a spontaneous test — %.</population>
        <group_list>
          <group group_id="O1">
            <title>COPD - Prevenar-13 (9)</title>
            <description>32 patients with COPD. Prevenar-13 (PCV13) vaccination.</description>
          </group>
          <group group_id="O2">
            <title>COPD - Pneumo-23 (11)</title>
            <description>23 patients with COPD. Pneumo-23 (PPV23) vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Phagocytic Activity in Patients With COPD at Baseline, 1, 2, and 6 Weeks After PCV13 and PPV13 Vaccination</title>
          <description>Phagocytic index (granulocytes), phagocytic index (monocytes), activity of a spontaneous HCT test (neutrophils), activity of an induced HCT test (neutrophils), percentage of HCT-positive white blood cells in a spontaneous test. The phagocytic index was calculated according to the following formula: phagocytic index = (total number of engulfed cells/total number of counted macrophages) × (number of macrophages containing engulfed cells/total number of counted macrophages) × 100 (phagocytic index)
The phagocytic index was calculated by counting at least 100 bacteria phagocytized by certain number of phagocytic cells/macrophages and expressed following formula (Mamnur Rashid 1997):
Phagocytic index = Total no. of phagocytized bacteria /No of phagocytic cells phagocytizing bacteria.
Activation index = % formazan positive cells (FPC) in NBT stimulated / % formazan positive cells (FPC) in NBT Spontaneous.</description>
          <population>Phagocytic index (granulocytes) — %, phagocytic index (monocytes) — %, activity of a spontaneous HCT test (neutrophils) — %, activity of an induced HCT test (neutrophils) — %, percentage of HCT-positive white blood cells in a spontaneous test — %.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phagocytic index (granulocytes) — baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" spread="7.6"/>
                    <measurement group_id="O2" value="63" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phagocytic index (granulocytes) — 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" spread="8.2"/>
                    <measurement group_id="O2" value="65" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phagocytic index (granulocytes) — 2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" spread="3.6"/>
                    <measurement group_id="O2" value="64.3" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phagocytic index (granulocytes) — 6 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" spread="3.2"/>
                    <measurement group_id="O2" value="66.5" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phagocytic index (monocytes) — baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.1" spread="5.4"/>
                    <measurement group_id="O2" value="74.6" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phagocytic index (monocytes) — 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.1" spread="4.6"/>
                    <measurement group_id="O2" value="75.3" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phagocytic index (monocytes) — 2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.4" spread="4.5"/>
                    <measurement group_id="O2" value="76.3" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phagocytic index (monocytes) — 6 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3" spread="3.7"/>
                    <measurement group_id="O2" value="78.1" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>activity of a spontaneous HCT test — baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="1.3"/>
                    <measurement group_id="O2" value="5" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>activity of a spontaneous HCT test — 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="3.1"/>
                    <measurement group_id="O2" value="5" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>activity of a spontaneous HCT test — 2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="4.7"/>
                    <measurement group_id="O2" value="7.2" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>activity of a spontaneous HCT test — 6 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="4.4"/>
                    <measurement group_id="O2" value="6.9" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>activity of an induced HCT test — baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="3.4"/>
                    <measurement group_id="O2" value="9.3" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>activity of an induced HCT test — 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" spread="2.9"/>
                    <measurement group_id="O2" value="10.8" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>activity of an induced HCT test — 2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" spread="3.1"/>
                    <measurement group_id="O2" value="10.4" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>activity of an induced HCT test — 6 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" spread="3.4"/>
                    <measurement group_id="O2" value="10.9" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>percentage of HCT-positive cells — baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="3.2"/>
                    <measurement group_id="O2" value="6" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>percentage of HCT-positive cells — 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="2.6"/>
                    <measurement group_id="O2" value="7.4" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>percentage of HCT-positive cells — 2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" spread="2.9"/>
                    <measurement group_id="O2" value="7.2" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>percentage of HCT-positive cells — 6 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" spread="3.6"/>
                    <measurement group_id="O2" value="6.7" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunophenotype of Blood Lymphocytes in Patients With COPD</title>
        <description>Immunophenotype of blood lymphocytes in patients with COPD at baseline, 1, 2 and 6 weeks after PCV13 and PPV23 vaccination. It was pre-specified to report data from only the &quot;COPD - Prevenar-13&quot; and the &quot;COPD - Pneumo-23&quot; Arms/Groups for this Outcome Measure&quot;. This is due to the fact that we tried to study the effect of PCV13 and PPV23 on immunity values. The study of the immunological effects of vaccination in the early post-vaccination period was carried out in 2 groups of patients: 20 patients with COPD vaccinated with PCV13; 20 patients with COPD vaccinated with PPV23. These patients were selected from patients of the main groups (COPD - Prevenar-13 (1), COPD - Pneumo-23 (3)).</description>
        <time_frame>Baseline, 1, 2, 6 weeks after PCV13 and PPV13 vaccination</time_frame>
        <population>CD3+, CD3+CD4+, CD3+CD8+, CD19+, CD3-CD16+CD56+, CD3+CD16+CD56+, CD3-HLA DR+, CD3+HLA DR+</population>
        <group_list>
          <group group_id="O1">
            <title>COPD - Prevenar-13 (1)</title>
            <description>20 patients with COPD. Prevenar-13 (PCV13) vaccination.</description>
          </group>
          <group group_id="O2">
            <title>COPD - Pneumo-23 (3)</title>
            <description>20 patients with COPD. Pneumo-23 (PPV23) vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunophenotype of Blood Lymphocytes in Patients With COPD</title>
          <description>Immunophenotype of blood lymphocytes in patients with COPD at baseline, 1, 2 and 6 weeks after PCV13 and PPV23 vaccination. It was pre-specified to report data from only the &quot;COPD - Prevenar-13&quot; and the &quot;COPD - Pneumo-23&quot; Arms/Groups for this Outcome Measure&quot;. This is due to the fact that we tried to study the effect of PCV13 and PPV23 on immunity values. The study of the immunological effects of vaccination in the early post-vaccination period was carried out in 2 groups of patients: 20 patients with COPD vaccinated with PCV13; 20 patients with COPD vaccinated with PPV23. These patients were selected from patients of the main groups (COPD - Prevenar-13 (1), COPD - Pneumo-23 (3)).</description>
          <population>CD3+, CD3+CD4+, CD3+CD8+, CD19+, CD3-CD16+CD56+, CD3+CD16+CD56+, CD3-HLA DR+, CD3+HLA DR+</population>
          <units>% of cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD3+, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.3" spread="4.8"/>
                    <measurement group_id="O2" value="69.6" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+, 1 week after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.7" spread="3.8"/>
                    <measurement group_id="O2" value="69.9" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+, 2 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" spread="2.8"/>
                    <measurement group_id="O2" value="71.3" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+, 6 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.9" spread="3.7"/>
                    <measurement group_id="O2" value="69.9" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+CD4+, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.9" spread="7.6"/>
                    <measurement group_id="O2" value="35.9" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+CD4+, 1 week after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7" spread="4.5"/>
                    <measurement group_id="O2" value="37.3" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+CD4+, 2 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.4" spread="5.8"/>
                    <measurement group_id="O2" value="36.9" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+CD4+, 6 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9" spread="5.4"/>
                    <measurement group_id="O2" value="37.8" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+CD8+, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2" spread="6.9"/>
                    <measurement group_id="O2" value="26.7" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+CD8+, 1 week after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5" spread="3.5"/>
                    <measurement group_id="O2" value="26.9" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+CD8+, 2 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" spread="5.1"/>
                    <measurement group_id="O2" value="27.6" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+CD8+, 6 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" spread="5.2"/>
                    <measurement group_id="O2" value="27.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19+, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="3.9"/>
                    <measurement group_id="O2" value="13.7" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19+, 1 week after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" spread="3"/>
                    <measurement group_id="O2" value="15.6" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19+, 2 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="2.5"/>
                    <measurement group_id="O2" value="14.9" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19+, 6 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" spread="3.8"/>
                    <measurement group_id="O2" value="14.5" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3-CD16+CD56+, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" spread="3.9"/>
                    <measurement group_id="O2" value="17.3" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3-CD16+CD56+, 1 week after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" spread="3"/>
                    <measurement group_id="O2" value="16.6" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3-CD16+CD56+, 2 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" spread="3.9"/>
                    <measurement group_id="O2" value="16.2" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3-CD16+CD56+, 6 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" spread="3.7"/>
                    <measurement group_id="O2" value="16.7" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+CD16+CD56+, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="3.8"/>
                    <measurement group_id="O2" value="10.6" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+CD16+CD56+, 1 week after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="4.2"/>
                    <measurement group_id="O2" value="11.9" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+CD16+CD56+, 2 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" spread="7.3"/>
                    <measurement group_id="O2" value="11.8" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+CD16+CD56+, 6 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" spread="5.3"/>
                    <measurement group_id="O2" value="10.8" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3-HLA DR+, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="4.2"/>
                    <measurement group_id="O2" value="10.7" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3-HLA DR+, 1 week after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" spread="3.8"/>
                    <measurement group_id="O2" value="11.9" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3-HLA DR+, 2 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="4.9"/>
                    <measurement group_id="O2" value="12.3" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3-HLA DR+, 6 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="5.1"/>
                    <measurement group_id="O2" value="11.3" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+HLA DR+, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" spread="3.5"/>
                    <measurement group_id="O2" value="11.5" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+HLA DR+, 1 week after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" spread="4.2"/>
                    <measurement group_id="O2" value="12.5" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+HLA DR+, 2 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="3.2"/>
                    <measurement group_id="O2" value="12.3" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3+HLA DR+, 6 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" spread="4.5"/>
                    <measurement group_id="O2" value="11.6" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IgA, IgM, IgG, IgE, Circulating Immune Complexes (CIC)</title>
        <description>IgA, IgM, IgG, IgE, circulating immune complexes (CIC) in serum at baseline, 1, 2 and 6 weeks after vaccination. It was pre-specified to report data from only the &quot;COPD - Prevenar-13&quot; and the &quot;COPD - Pneumo-23&quot; Arms/Groups for this Outcome Measure&quot;. This is due to the fact that we tried to study the effect of PCV13 and PPV23 on immunity values. The study of the immunological effects of vaccination in the early post-vaccination period was carried out in 2 groups of patients: 20 patients with COPD vaccinated with PCV13; 20 patients with COPD vaccinated with PPV23. These patients were selected from patients of the main groups (COPD - Prevenar-13 (1), COPD - Pneumo-23 (3)).</description>
        <time_frame>Baseline, 1, 2, 6 weeks after PCV13 and PPV13 vaccination in COPD</time_frame>
        <group_list>
          <group group_id="O1">
            <title>COPD - Prevenar-13 (1)</title>
            <description>20 patients with COPD. Prevenar-13 (PCV13) vaccination.</description>
          </group>
          <group group_id="O2">
            <title>COPD - Pneumo-23 (3)</title>
            <description>20 patients with COPD. Pneumo-23 (PPV23) vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>IgA, IgM, IgG, IgE, Circulating Immune Complexes (CIC)</title>
          <description>IgA, IgM, IgG, IgE, circulating immune complexes (CIC) in serum at baseline, 1, 2 and 6 weeks after vaccination. It was pre-specified to report data from only the &quot;COPD - Prevenar-13&quot; and the &quot;COPD - Pneumo-23&quot; Arms/Groups for this Outcome Measure&quot;. This is due to the fact that we tried to study the effect of PCV13 and PPV23 on immunity values. The study of the immunological effects of vaccination in the early post-vaccination period was carried out in 2 groups of patients: 20 patients with COPD vaccinated with PCV13; 20 patients with COPD vaccinated with PPV23. These patients were selected from patients of the main groups (COPD - Prevenar-13 (1), COPD - Pneumo-23 (3)).</description>
          <units>g/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IgA, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.57" spread="1.18"/>
                    <measurement group_id="O2" value="3.33" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA, 1 week after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.74" spread="1.25"/>
                    <measurement group_id="O2" value="3.39" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA, 2 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.79" spread="1.26"/>
                    <measurement group_id="O2" value="3.52" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA, 6 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.63" spread="1.13"/>
                    <measurement group_id="O2" value="3.56" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.21"/>
                    <measurement group_id="O2" value="1.26" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM, 1 week after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="0.62"/>
                    <measurement group_id="O2" value="1.3" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM, 2 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.17"/>
                    <measurement group_id="O2" value="1.3" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM, 6 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.23"/>
                    <measurement group_id="O2" value="1.34" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" spread="1.13"/>
                    <measurement group_id="O2" value="11.6" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG, 1 week after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" spread="0.8"/>
                    <measurement group_id="O2" value="11.7" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG, 2 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="1.04"/>
                    <measurement group_id="O2" value="11.9" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG, 6 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" spread="0.57"/>
                    <measurement group_id="O2" value="11.8" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgE, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" spread="42"/>
                    <measurement group_id="O2" value="120" spread="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgE, 1 week after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126" spread="87"/>
                    <measurement group_id="O2" value="118" spread="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgE, 2 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118" spread="74"/>
                    <measurement group_id="O2" value="120" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgE, 6 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119" spread="51"/>
                    <measurement group_id="O2" value="120" spread="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CIC, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.067" spread="0.02"/>
                    <measurement group_id="O2" value="0.073" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CIC, 1 week after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.086" spread="0.01"/>
                    <measurement group_id="O2" value="0.077" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CIC, 2 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.079" spread="0.015"/>
                    <measurement group_id="O2" value="0.08" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CIC, 6 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.073" spread="0.016"/>
                    <measurement group_id="O2" value="0.079" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD45RO</title>
        <description>CD45RO expression on lymphocytes in serum at baseline, 1 and 4 years after vaccination. These patients were selected from patients of the main groups.</description>
        <time_frame>Baseline, 1 and 4 years after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>COPD With Prevenar-13 (1)</title>
            <description>32 patients with COPD. Standard therapy with Prevenar-13.
Prevenar-13: Conjugate 13 serotype pneumococcal vaccine</description>
          </group>
          <group group_id="O2">
            <title>Asthma With Prevenar 13 (2)</title>
            <description>33 patients with asthma. Standard therapy with Prevenar 13.
Prevenar-13: Conjugate 13 serotype pneumococcal vaccine</description>
          </group>
          <group group_id="O3">
            <title>COPD With Pneumo-23 (3)</title>
            <description>23 patients with COPD. Standard therapy with Pneumo-23.
Pneumo-23: Polysaccharide 23-valent pneumococcal vaccine.</description>
          </group>
          <group group_id="O4">
            <title>Asthma With Pneumo-23 (4)</title>
            <description>25 patients with asthma. Standard therapy with Pneumo-23.
Pneumo-23: Polysaccharide 23-valent pneumococcal vaccine.</description>
          </group>
          <group group_id="O5">
            <title>COPD With Pneumo-23/Prevenar-13 (5)</title>
            <description>32 patients with COPD. Standard therapy, vaccinated with PPV23/PCV13.
Prevenar-13: Conjugate 13 serotype pneumococcal vaccine
Pneumo-23: Polysaccharide 23-valent pneumococcal vaccine.</description>
          </group>
          <group group_id="O6">
            <title>Asthma With Pneumo-23/Prevenar-13 (6)</title>
            <description>18 patients with Asthma. Standard therapy, vaccinated with PPV23/PCV13.
Prevenar-13: Conjugate 13 serotype pneumococcal vaccine
Pneumo-23: Polysaccharide 23-valent pneumococcal vaccine.</description>
          </group>
          <group group_id="O7">
            <title>COPD With Prevenar-13/Pneumo-23 (7)</title>
            <description>25 patients with COPD. Standard therapy, vaccinated with PCV13/PPV23.
Prevenar-13: Conjugate 13 serotype pneumococcal vaccine
Pneumo-23: Polysaccharide 23-valent pneumococcal vaccine.</description>
          </group>
          <group group_id="O8">
            <title>Asthma With Prevenar-13/Pneumo-23 (8)</title>
            <description>27 patients with Asthma. Standard therapy, vaccinated with PCV13/PPV23.
Prevenar-13: Conjugate 13 serotype pneumococcal vaccine
Pneumo-23: Polysaccharide 23-valent pneumococcal vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>CD45RO</title>
          <description>CD45RO expression on lymphocytes in serum at baseline, 1 and 4 years after vaccination. These patients were selected from patients of the main groups.</description>
          <units>U</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="15"/>
                <count group_id="O8" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD45RO, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.01"/>
                    <measurement group_id="O2" value="0.1" spread="0.01"/>
                    <measurement group_id="O3" value="0.1" spread="0.01"/>
                    <measurement group_id="O4" value="0.1" spread="0.01"/>
                    <measurement group_id="O5" value="0.1" spread="0.01"/>
                    <measurement group_id="O6" value="0.1" spread="0.01"/>
                    <measurement group_id="O7" value="0.1" spread="0.01"/>
                    <measurement group_id="O8" value="0.1" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45RO, 1 year after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.04"/>
                    <measurement group_id="O2" value="0.2" spread="0.02"/>
                    <measurement group_id="O3" value="0.1" spread="0.01"/>
                    <measurement group_id="O4" value="0.15" spread="0.01"/>
                    <measurement group_id="O5" value="0.47" spread="0.06"/>
                    <measurement group_id="O6" value="0.67" spread="0.13"/>
                    <measurement group_id="O7" value="0.71" spread="0.12"/>
                    <measurement group_id="O8" value="0.73" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD45RO, 4 years after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.03"/>
                    <measurement group_id="O2" value="0.2" spread="0.015"/>
                    <measurement group_id="O3" value="0.05" spread="0.01"/>
                    <measurement group_id="O4" value="0.1" spread="0.01"/>
                    <measurement group_id="O5" value="0.31" spread="0.02"/>
                    <measurement group_id="O6" value="0.32" spread="0.08"/>
                    <measurement group_id="O7" value="0.59" spread="0.1"/>
                    <measurement group_id="O8" value="0.59" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Specific IgG Levels in Vaccinated Patients With COPD to S. Pneumoniae Serotypes</title>
        <description>Mean specific IgG levels in vaccinated patients with COPD to S. pneumoniae serotypes at baseline, 6 and 12 months after vaccination</description>
        <time_frame>Baseline, 1 and 12 months after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>COPD - Prevenar-13</title>
            <description>32 patients with COPD. Prevenar-13 (PCV13) vaccination.</description>
          </group>
          <group group_id="O2">
            <title>COPD - Pneumo-23</title>
            <description>23 patients with COPD. Pneumo-23 (PPV23) vaccination.</description>
          </group>
          <group group_id="O3">
            <title>COPD - Pneumo-23/Prevenar-13</title>
            <description>32 patients with COPD, PPV23/PCV13.
PPV23 vaccination was first, PCV13 vaccination was after 12 months after PPV23.</description>
          </group>
          <group group_id="O4">
            <title>COPD - Prevenar-13/Pneumo-23</title>
            <description>25 patients with COPD. PCV13/PPV23 vaccination.
PCV13 vaccination was first, PPV23 vaccination was after 2 months after PCV13.</description>
          </group>
        </group_list>
        <measure>
          <title>Specific IgG Levels in Vaccinated Patients With COPD to S. Pneumoniae Serotypes</title>
          <description>Mean specific IgG levels in vaccinated patients with COPD to S. pneumoniae serotypes at baseline, 6 and 12 months after vaccination</description>
          <units>U/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.7" lower_limit="40.9" upper_limit="113.1"/>
                    <measurement group_id="O2" value="66.9" lower_limit="44" upper_limit="92.1"/>
                    <measurement group_id="O3" value="87.5" lower_limit="61.7" upper_limit="132.3"/>
                    <measurement group_id="O4" value="88" lower_limit="57.1" upper_limit="121.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.7" lower_limit="88.9" upper_limit="179.9"/>
                    <measurement group_id="O2" value="106.9" lower_limit="52" upper_limit="284.5"/>
                    <measurement group_id="O3" value="119.4" lower_limit="76.9" upper_limit="160.9"/>
                    <measurement group_id="O4" value="142.2" lower_limit="90.3" upper_limit="200.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.9" lower_limit="69.2" upper_limit="157.1"/>
                    <measurement group_id="O2" value="94.9" lower_limit="48" upper_limit="253.1"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="136" lower_limit="97.4" upper_limit="193.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days after vaccination</time_frame>
      <group_list>
        <group group_id="E1">
          <title>COPD - Prevenar-13 (1)</title>
          <description>32 patients with COPD. Prevenar-13 (PCV13) vaccination.</description>
        </group>
        <group group_id="E2">
          <title>Asthma - Prevenar-13 (2)</title>
          <description>33 patients with asthma. Prevenar-13 (PCV13) vaccination.</description>
        </group>
        <group group_id="E3">
          <title>COPD - Pneumo-23 (3)</title>
          <description>23 patients with COPD. Pneumo-23 (PPV23) vaccination.</description>
        </group>
        <group group_id="E4">
          <title>Asthma - Pneumo-23 (4)</title>
          <description>25 patients with asthma. Pneumo-23 (PPV23) vaccination.</description>
        </group>
        <group group_id="E5">
          <title>COPD - Pneumo-23/Prevenar-13 (5)</title>
          <description>32 patients with COPD, PPV23/PCV13.
PPV23 vaccination was first, PCV13 vaccination was after 12 months after PPV23.</description>
        </group>
        <group group_id="E6">
          <title>Asthma - Pneumo-23/Prevenar-13 (6)</title>
          <description>18 patients with Asthma. PPV23/PCV13.
PPV23 vaccination was first, PCV13 vaccination was after 12 months after PPV23.</description>
        </group>
        <group group_id="E7">
          <title>COPD - Prevenar-13/Pneumo-23 (7)</title>
          <description>25 patients with COPD. PCV13/PPV23 vaccination.
PCV13 vaccination was first, PPV23 vaccination was after 2 months after PCV13.</description>
        </group>
        <group group_id="E8">
          <title>Asthma - Prevenar-13/Pneumo-23 (8)</title>
          <description>27 patients with Asthma. PCV13/PPV23 vaccination.
PCV13 vaccination was first, PPV23 vaccination was after 2 months after PCV13.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Andrei Dmitrievich Protasov, Professor Mikhail Petrovich Kostinov</name_or_title>
      <organization>Samara State Medical University, Institute of Sera and Vaccines RAS</organization>
      <phone>+79277444126</phone>
      <email>crosss82@mail.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

